Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11230-021-10005-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- The study aimed to create a new prognostic model to estimate the risk of pulmonary complications after elective surgery, which is the leading cause of post-surgery death.
- Data from a large international cohort of over 86,000 patients was used, applying machine learning techniques to identify risk factors for complications like pneumonia and respiratory distress.
- The model, named the GSU-Pulmonary Score, was validated with additional cohorts and is available as an online tool to assist in patient care and resource management, especially important during pandemic recovery.
Background: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with usual care on duration of hospital stay for children with PIMS-TS and to compare tocilizumab (anti-IL-6 receptor monoclonal antibody) or anakinra (anti-IL-1 receptor antagonist) with usual care for those with inflammation refractory to initial treatment.
Methods: We did this randomised, controlled, open-label, platform trial in 51 hospitals in the UK.
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet Diabetes Endocrinol
December 2023
Background: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19.
Methods: In the randomised, controlled, open-label RECOVERY trial, several possible treatments are compared with usual care in patients hospitalised with COVID-19.
Article Synopsis
- A study evaluated the effects of a higher dose of corticosteroids on COVID-19 patients who needed oxygen or ventilatory support, building on previous findings that low-dose corticosteroids reduced mortality in similar patients.
- The research was part of the RECOVERY trial, which randomly assigned patients to receive either higher dose corticosteroids or usual care with a lower dose, measuring 28-day mortality rates as the primary outcome.
- From May 2021 to May 2022, 1,272 patients were included, with notable participation from Asia and the UK; results showed that nearly all of the patients who received usual care also received some form of low-dose corticosteroids.
Background: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1-2 inhibitor, for the treatment of patients admitted to hospital with COVID-19.
Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!